D E Reece
Overview
Explore the profile of D E Reece including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
798
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Foley R, Kaedbey R, Song K, Venner C, White D, Doucette S, et al.
Curr Oncol
. 2020 Nov;
27(5):270-274.
PMID: 33173379
The coronavirus disease 2019 (covid-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 has necessitated changes to the way patients with chronic diseases are managed. Given that...
2.
Seki J, Sakurai N, Lam W, Reece D
Curr Oncol
. 2017 Sep;
24(4):e328-e332.
PMID: 28874903
Despite progressive treatments with tandem stem-cell transplantation, patients with incurable myeloma eventually succumb to relapsed or refractory disease if left untreated. Promising agents such as proteasome inhibitors and immunomodulating imide...
3.
Areethamsirikul N, Masih-Khan E, Chu C, Jimenez-Zepeda V, Reece D, Trudel S, et al.
Bone Marrow Transplant
. 2015 Jan;
50(3):375-9.
PMID: 25599165
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) is a highly active three-drug induction regimen for untreated transplant-eligible multiple myeloma patients. Although CyBorD has been evaluated only in the phase 2 setting in...
4.
Jimenez-Zepeda V, Reece D, Trudel S, Chen C, Tiedemann R, Kukreti V
Bone Marrow Transplant
. 2014 Oct;
50(2):204-8.
PMID: 25347006
The role of auto-SCT in the treatment of multiple myeloma (MM) in the era of novel agents continues to evolve. It is now clear that the depth of response and...
5.
Kouroukis T, Baldassarre F, Haynes A, Imrie K, Reece D, Cheung M
Curr Oncol
. 2014 Aug;
21(4):e573-603.
PMID: 25089109
We conducted a systematic review to determine the appropriate use of bortezomib alone or in combination with other agents in patients with multiple myeloma (mm). We searched medline, embase, the...
6.
Kouroukis C, Baldassarre F, Haynes A, Imrie K, Reece D, Cheung M
Clin Oncol (R Coll Radiol)
. 2013 Dec;
26(2):110-9.
PMID: 24321107
Aims: Bortezomib (Velcade™, PS-341), a first-in-class proteasome inhibitor, has been extensively studied either alone or in combination with other agents for the treatment of multiple myeloma. We created a provincial...
7.
Freytes C, Vesole D, LeRademacher J, Zhong X, Gale R, Kyle R, et al.
Bone Marrow Transplant
. 2013 Nov;
49(3):416-21.
PMID: 24270389
There is no standard therapy for multiple myeloma relapsing after an autotransplant. We compared the outcomes of a second autotransplant (N=137) with those of an allotransplant (N=152) after non-myeloablative or...
8.
Dubrey S, Reece D, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, et al.
QJM
. 2011 Jul;
104(11):957-70.
PMID: 21752867
Background: Bortezomib is approved for the treatment of multiple myeloma and a role has been suggested in the treatment of systemic AL amyloidosis (AL). Methods: In this phase 1 dose-escalation...
9.
Hari P, Zhang M, Roy V, Perez W, Bashey A, To L, et al.
Leukemia
. 2009 Mar;
23(8):1528-34.
PMID: 19322205
The international staging system (ISS) for multiple myeloma (MM) is a validated alternative to the Durie-Salmon staging system (DSS) for predicting survival at diagnosis. We compared these staging systems for...
10.
Reeder C, Reece D, Kukreti V, Chen C, Trudel S, Hentz J, et al.
Leukemia
. 2009 Feb;
23(7):1337-41.
PMID: 19225538
We have studied a three-drug combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) on a 28-day cycle in the treatment of newly diagnosed multiple myeloma (MM) patients to assess response and...